logo

Your gate­way

to finance

and inno­va­tion

in Cen­tral Europe

Gen­eral

Fourth Cen­tral Euro­pean Life Sci­ence Invest­ment Conference

Hotel Stary, Krakow, 2324 Octo­ber 2014


    • Early bird registration

until 5th Sep­tem­ber 2014

950 PLN + 23% VAT

or €290 + 23% VAT


    • Stan­dard registration

from 6th Sep­tem­ber 2014

1450zl + 23% VAT

or €440 + 23% VAT


    • Accom­pa­ny­ing persons

If you would like to bring a friend please be in contact.

If there is suf­fi­cient inter­est we will develop an interesting

agenda for accom­pa­ny­ing persons.

There will be a mod­est fee.


    • Extra din­ner guest

250zl + 23% VAT

70 + 23% VAT


By reg­is­ter­ing you acknowl­edge hav­ing read the dis­claimer and under­stood the can­cel­la­tion policy


Pay­ment by bank trans­fer in Euros to: Nordea Bank in Krakow

94 1440 1127 0000 0000 1386 1129 in Pol­ish zloty to:

Nordea Bank in Krakow

68 1440 1127 0000 0000 1134 2701

Reg­is­ter

Agenda

This year’s theme:

“Financ­ing, Com­mer­cial­i­sa­tion, & Col­lab­o­ra­tion: oppor­tu­ni­ties in Cen­tral Europe”

Agenda cor­rect on 19 Octo­ber 2014

22 Octo­ber 2014

18.00

Reg­is­tra­tion open

18.00

Pre-​conference Drinks Recep­tion at the Hotel Stary

23 Octo­ber 2014

MAIN CON­FER­ENCE STARTS

08.00 Reg­is­tra­tion Open

09.45

Wel­come
Leszek Grabar­czyk, The National Cen­tre for Research and Devel­op­ment; NCBR (Poland)

Roland Kozlowski, LSBC (Poland)

10.00 Ses­sion: Some per­spec­tives on life sci­ence investment

Chair: Roland Kozlowski

10.00

Talk: Early stage life sci­ence invest­ment, pos­i­tive and neg­a­tive expe­ri­ences in West­ern Markets

Cather­ine Beech (UK)

10.30

Talk: Clin­i­cal tri­als in Poland and Cen­tral Europe – case stud­ies, prob­lems and solutions

Mar­iusz Ole­jniczak (Assign Clin­i­cal Research Sp. z o.o., Poland)

11.00 Cof­fee & Networking


11.45 Ses­sion: Private-​public part­ner­ship and seed­ing inno­va­tion: first blos­soms emerge

Chair: Roland Kozlowski

11.45

Talk: Bridge VC Leszek Grabar­czyk

The National Cen­tre for Research and Devel­op­ment; NCBR (Poland)

12.00

Talk: The role of the Pol­ish Agency for Enter­prise Devel­op­ment in fund­ing inno­va­tion.
Michal Banka, The Pol­ish Agency for Enter­prise Devel­op­ment (Poland)

12.15

Invest­ment opportunities:

Four Invest­ment oppor­tu­ni­ties emerg­ing from the Bridge VC pro­gram Pre­sented by LSBC:

Roland Kozlowski (Brief Overview)

Krzysztof Jakubczak (devices)

Marta Osęka (devices)

Maciej Paszewski (therapeutics)

Edyta Niem­czyk (diagnostics)


13.15 Net­work­ing lunch

14.15 Ses­sion: Sci­ence parks and incu­ba­tors estate agen­cies or hot-​beds of innovation?

Chair & Fire­side Dis­cus­sion Host: Marcin Szumowski

Talk: Incu­ba­tor case study

Glenn Crocker (Bioc­ity; UK)

14.45

Fire­side dis­cus­sion: What works and what doesn’t lessons from estab­lished players

Ben­jamin Thier­ing (Berlin Part­ner, Germany)

Glenn Crocker (CEO, Bioc­ity; UK)

Łukasz Nier­adko (Wro­claw Research Cen­tre EIT+; Poland)

15.30

TEA & Networking

16.15

Panel Dis­cus­sion:Generic or inno­v­a­tive prod­ucts or inno­va­tion in gener­ics what’s best for our region.

Panel Mod­er­a­tor: Steven Powell

Chas Boun­tra (Struc­tural Genomics Con­sor­tium, UK)

Klaus Mar­tin (Pol­pharma Bio­log­ics, Poland)

Bogusław Sieczkowski(Selvita, Poland)

Marek Borzestowski (Giza Pol­ish Ven­tures, Poland)

Kreske Nick­elsen (JPIF, Germany)

17.00

Con­fer­ence close for the day

19.15

Net­work­ing drinks, Con­fer­ence Din­ner, Live Music: Restau­rant Pod Roza

24 Octo­ber 2014

7.45

Inno­va­tion is Great — Busi­ness Breakfast

Busi­ness Break­fast Hosted by UKTI and the British Embassy in War­saw. How can Pol­ish and UK com­pa­nies collaborate.

Mod­er­a­tor: Mark Tre­herne (UK)

Ses­sion Starts 9.15 Com­mer­cial­i­sa­tion and financing

Chair: Cather­ine Beech

9.15

Talk: Com­mer­cial­is­ing med­ical devices

Romeer Fer­nan­des (Switzerland)

9.45

Panel dis­cus­sion: How to finance, com­mer­cialise and gen­er­ate value from devices

Panel Mod­er­a­tor: Cather­ine Beech

Regina Hodits (Welling­ton Part­ners, Germany)

Romeer Fer­nan­des (Switzerland)

Janusz Golus (Philips Health­care, Poland)

Marcin Szu­mowski (Med­ical­go­rith­mics, Poland)

10.30

Com­pany Showcase

Pre­sen­ta­tions from 4 Pol­ish com­pa­nies seek­ing to expand their busi­ness internationally

Selvita: Bogusław Sieczkowski

Pol­pharma Bio­log­ics: Tomasz Góralczyk

BLIRT: Dominik Ziętkowski

Pro­teon Phar­ma­ceu­ti­cals:Jef­fery Grady

11.15

Cof­fee and networking

11.45

Talk: Com­mer­cial­is­ing plat­forms and diagnostics

Alex Yule (Alexan­der Yule Con­sult­ing, UK)

12.30

Panel dis­cus­sion: How to finance, develop and gen­er­ate value for such opportunities

Mod­er­a­tor: Roland Kozlowski

Mike Romanos (Crescendo Bio­log­ics, UK)

Alex Yule (Alexan­der Yule Con­sult­ing, UK)

Andrew Allars (Wyvern Asset Man­age­ment, UK)

Steven Pow­ell (Gilde, Belgium)

13.15

Sum­ming up & Con­fer­ence Close

Roland Kozlowski (LSBC)

13.3015.30

Round­table dis­cus­sion for Investors Inter­ested in Invest­ment in inno­va­tion in Poland Pri­vate Pub­lic Part­ner­ship oppor­tu­ni­ties over lunch.

For­eign vis­i­tors include: Wyw­ern Asset Man­age­ment, Giza Ven­ture Cap­i­tal, Welling­ton Part­ners , JPIF, Gilde

Speak­ers

        • Andy Allars
          Andy Allars
        • Michał Bańka
          Michał Bańka
        • Catherine Beech
          Cather­ine Beech
        • Marek Borzestowski
          Marek Borzestowski
        • Chas Bountra
          Chas Boun­tra
        • Glenn Crocker
          Glenn Crocker
        • Janusz Golus
          Janusz Golus
        • Leszek Grabarczyk
          Leszek Grabar­czyk
        • Jeffery Grady
          Jef­fery Grady
        • Regina Hodits
          Regina Hodits
        • Krzysztof Jakubczak
          Krzysztof Jakubczak
        • Roland Kozlowski
          Roland Kozlowski
        • Klaus Martin
          Klaus Mar­tin
        • Edyta Niemczyk
          Edyta Niem­czyk
        • Lukasz Nieradko
          Lukasz Nier­adko
        • Marta Oseka
          Marta Oseka
        • Maciej Paszewski
          Maciej Paszewski
        • Steven Powell
          Steven Pow­ell
        • Pawel Przewiezlikowski
          Pawel Przewie­z­likowski
        • Mike Romanos
          Mike Romanos
        • Benjamin Thiering
          Ben­jamin Thiering
        • Alexander Yule
          Alexan­der Yule
        • Dominik Zietkowski
          Dominik Zietkowski
        • Romeer Fernandes
          Romeer Fer­nan­des
        • Mariusz Olejniczak
          Mar­iusz Olejniczak
        • Bogusław Sieczkowski
          Bogusław Sieczkowski
        • Mark Treherne
          Mark Tre­herne
        • Marcin Szumowski
          Marcin Szu­mowski
        • Adam Kruszewski
          Adam Kruszewski
Andrew Allars

Andrew Allars

Andrew Allars B.Sc., MBA (56), is CEO of Wyvern Asset Man­age­ment. WAM is the fund man­ager of the Wyvern Seed Fund, invest­ing in spin-​out oppor­tu­ni­ties from the Uni­ver­si­ties of Bris­tol and Southamp­ton. He is also Man­ag­ing Part­ner of ven­ture con­sul­tancy, Anauel LLP.He was orig­i­nally trained in chem­istry and bio­chem­istry at the Uni­ver­sity of Southamp­ton and spent 10 years work­ing in sales and mar­ket­ing in the bio­science indus­try, at com­pa­nies such as Phar­ma­cia LKB and ICI.

After com­plet­ing an MBA at Cran­field Man­age­ment School, he entered the ven­ture cap­i­tal indus­try in 1990. He was, until 2004, Head of Life Sci­ences at Pre­lude Ven­tures Lim­ited, a spe­cial­ist ven­ture cap­i­tal investor in early stage tech­nol­ogy com­pa­nies. Dur­ing his time at Pre­lude he was closely involved in sev­eral suc­cess­ful start up bio­science com­pa­nies includ­ing Acam­bis plc (now part of Sanofi), Quad­rant Health­care plc (now part of Vec­tura plc), Danby Med­ical Lim­ited (now part of Bax­ter Inc) and Oxford Bio­med­ica plc.

At Anauel he has worked with a num­ber of ven­ture cap­i­tal­ists, in par­tic­u­lar the Dutch group, Life Sci­ence Part­ners, and a num­ber of start-​up com­pa­nies includ­ing Azel­lon Ltd.


Michał Bańka

Michał Bańka

Michał Bańka worked at the Min­istry of Econ­omy to man­age and medi­ate imple­men­ta­tion of sev­eral EU funded pro­grams. Since 2006 his respon­si­bil­i­ties have included run­ning the finan­cial depart­ments of three Pro­grams: (1) Improv­ing the Com­pet­i­tive­ness of Enter­prises, (2) Inno­v­a­tive Econ­omy and (3) Infra­struc­ture and Envi­ron­ment. He has held the posi­tions of Deputy Direc­tor, and from 2012 Direc­tor of the Depart­ment of Busi­ness Envi­ron­ment Insti­tu­tion Sup­port of the Pol­ish Agency for Enter­prise Devel­op­ment. His respon­si­bil­i­ties include: (1) Pro­vid­ing sup­port for busi­ness incu­ba­tors in find­ing inno­v­a­tive ideas and cap­i­tal input for “Start-​ups”, (2) Sup­port of the ‘Busi­ness Angels’ Net­work, (3) Sup­port for Busi­ness Envi­ron­ment Insti­tu­tions, (4)

Orig­i­na­tor, Loan fund man­agers for micro and small enter­prises with the par­tic­i­pa­tion of busi­ness angel or ven­ture cap­i­tal fund.

Financ­ing of advi­sory ser­vices that are nec­es­sary to attract exter­nal investors. His busi­ness career is com­bined with an aca­d­e­mic role involv­ing teach­ing at the Fac­ulty of Polit­i­cal Sci­ence at War­saw Uni­ver­sity. He is the project man­ager and gen­eral exec­u­tive of R & D projects of the Min­istry of Sci­ence and Higher Edu­ca­tion and author and co-​author of sev­eral mono­graphs and sci­en­tific articles.


Catherine Beech

Cather­ine Beech

Dr Cather­ine Beech OBE is an entre­pre­neur who focuses on start up com­pa­nies in the life sci­ences sec­tor. She began her career work­ing as a doc­tor within the NHS join­ing the phar­ma­ceu­ti­cal indus­try over 20 years ago. In 1999 Cather­ine co-​founded Cam­bridge Gate­way Fund, an early stage fund that invested pri­mar­ily in spin­outs from UK Uni­ver­si­ties. From 2006 until 2008 Cather­ine was CEO of Aitua, a seed invest­ment com­pany that invested in spin­outs from the BBSRC facil­ity in Cam­bridge. Cather­ine has invested in and taken a posi­tion on the board of circa 10 early stage com­pa­nies help­ing them to grow and in some cases achieve suc­cess­ful IPO’s or trade sales.

As a mem­ber of the Tech­nol­ogy Strat­egy Board, Cather­ine was instru­men­tal in sup­port­ing the UK gov­ern­ment to define the UK strat­egy for Life Sci­ences. In 2008 she was awarded an OBE for Ser­vices to Tech­nol­ogy and Innovation.


Marek Borzestowski

Marek Borzestowski

Marek Borzestowski is a ser­ial entre­pre­neur, founder of suc­cess­ful inter­net busi­nesses and a part­ner in the Pol­ish Israeli VC Fund ‐ Giza Pol­ish Ven­tures. He has over 20 years of expe­ri­ence as a founder and mem­ber of the boards of Wirtu­alna Pol­ska, Gru​per​.pl, Mind the Kids, Inteli­WISE and a founder of a first Pol­ish think tank – Sobieski Insti­tute and Sturtup Hub Poland Foun­da­tion. Marek is actively invest­ing in com­pa­nies that focus on dig­i­tal, mobile, data ana­lyt­ics and biotech­nol­ogy. He grad­u­ated from a Tech­ni­cal Uni­ver­sity of Gdansk, stud­ied at the Uni­ver­sity of Wales in Swansea in the UK and in the Nuclear Research Cen­tre in Karl­sruhe in Germany.


Chas Bountra

Chas Boun­tra

Chas is Pro­fes­sor of Trans­la­tional Med­i­cine in the Nuffield Depart­ment of Clin­i­cal Med­i­cine and Asso­ciate Mem­ber of the Depart­ment of Phar­ma­col­ogy at the Uni­ver­sity of Oxford. He is also a Vis­it­ing Pro­fes­sor in Neu­ro­science and Men­tal Health at Impe­r­ial Col­lege, Lon­don. Chas is an invited expert on sev­eral gov­ern­ment and char­i­ta­ble research fund­ing bod­ies, and an advi­sor for many aca­d­e­mic, biotech and pharma drug dis­cov­ery programmes.

Prior to com­ing back to Oxford six years ago, Chas was Vice Pres­i­dent and Head of Biol­ogy at Glax­o­SmithK­line. He was involved in the iden­ti­fi­ca­tion of more than 40 clin­i­cal can­di­dates for many gastro-​intestinal, inflam­ma­tory and neuro-​psychiatric dis­eases. More than 20 of these mol­e­cules pro­gressed into patient stud­ies and more than five of these deliv­ered suc­cess­ful “Proof of Con­cept” data and hence pro­gressed into late stage devel­op­ment. He was involved in the launch and devel­op­ment of the first treat­ment for Irri­ta­ble Bowel Syn­drome (Alos­etron) and was the first to show that neu­rokinin NK1 antag­o­nists are anti-​emetic in pre­clin­i­cal and clin­i­cal studies.

His cur­rent inter­ests are i) using X ray struc­tures of novel human pro­teins to gen­er­ate small mol­e­cule inhibitors, screen­ing in human cells to iden­tify novel tar­gets for drug dis­cov­ery, and then devel­op­ing clin­i­cal can­di­dates for eval­u­a­tion in patients, pre-​competitively ii) focussing on epi­ge­netic and genet­i­cally iden­ti­fied pro­teins, because these are likely to rep­re­sent bet­ter tar­gets for drug dis­cov­ery, for many can­cer, inflam­ma­tory, meta­bolic and neuro-​psychiatric dis­eases iii) work­ing with col­leagues in Oxford to build major pro­grammes in rare dis­eases and in Alzheimers Dis­ease, and cre­at­ing a “BioEsca­la­tor” for the rapid trans­la­tion of SGC sci­ence and iv) build­ing stronger links with local hos­pi­tals, patient groups, reg­u­la­tory agen­cies, pri­vate investors, CROs, biotechs and large pharma com­pa­nies, to cre­ate a new, more effi­cient ecosys­tem for pio­neer drug discovery.

Chas believes the SGC has become a leader in human pro­tein struc­tural biol­ogy and epi­ge­net­ics chem­i­cal biol­ogy, and is arguably one of the most suc­cess­ful open inno­va­tion, pub­lic – pri­vate part­ner­ships in the world. Fur­ther­more, with the many recent local devel­op­ments (Tar­get Dis­cov­ery Insti­tute, Kennedy Insti­tute), he believes Oxford is emerg­ing as one of the major aca­d­e­mic drug dis­cov­ery cen­tres in Europe. He has given over 300 invited lec­tures. In 2012 he was voted one of the “top inno­va­tors in the industry”.


Glenn Crocker

Glenn Crocker

Glenn Crocker is the CEO of BioC­ity – the UK’s lead­ing life sci­ences busi­ness incu­ba­tor. He is an expert in life sci­ence start up mar­ket, estab­lish­ing life sci­ence busi­ness ecosys­tems and the repur­pos­ing of redun­dant phar­ma­ceu­ti­cal facil­i­ties. Career highlights:

Glenn has a BSc in Genet­ics from Not­ting­ham Uni­ver­sity and a DPhil in Immunol­ogy from Oxford Uni­ver­sity. Fol­low­ing a short time in post-​doctoral research he joined Ernst & Young and qual­i­fied as a char­tered accountant.

With Ernst & Young he focussed on biotech com­pa­nies in the South of Eng­land: then moved with the Prac­tice to Palo Alto, Cal­i­for­nia work­ing with, among oth­ers, Alza, Incyte, Gilead and Tularik. He authored the company’s annual life sci­ence indus­try reports. He returned to Cam­bridge, UK, he headed up the company’s UK Biotech Prac­tice lead­ing its devel­op­ment before tak­ing on the role of CEO at BioC­ity Not­ting­ham in 2003. Dur­ing his 10 years at BioC­ity Not­ting­ham he has grown this ex Boots R&D City Cen­tre site into a prof­itable busi­ness through his inno­v­a­tive approach to busi­ness incu­ba­tion where the focus is on the com­pany and its abil­ity to sur­vive and grow prof­itably. This approach attracted 96 com­pa­nies to start life with BioC­ity and 91% of those com­pa­nies remain in busi­ness and con­tinue to grow.

Glenn was the co-​founder of R5 Phar­ma­ceu­ti­cals (which was sub­se­quently sold to Aesica) and BioAs­cent Dis­cov­ery and has been closely involved in the estab­lish­ment of Xeno­gesis and a num­ber of other life sci­ence companies.

He has led the expan­sion of BioC­ity into Scot­land; estab­lished col­lab­o­ra­tions with Boots, a mem­ber of Alliance Boots, to cre­ate MediC­ity – the health, beauty and busi­ness inno­va­tion hub; and was appointed by Astra Zeneca to cre­ate a Bio­Hub at its Alder­ley Park site, Cheshire. BioC­ity and Glenn have received a num­ber of awards in recog­ni­tion of these achieve­ments. He is the author of the UK Life Sci­ences Start-​up Report, an annual sur­vey of the UK start up sec­tor and co-​founder of the UK Bio-​incubation Forum – a lead­ing mem­ber­ship asso­ci­a­tion and inde­pen­dent voice for life sci­ence busi­ness incu­ba­tion and accel­er­ated growth, influ­enc­ing pol­icy at local, national, Euro­pean and inter­na­tional level.


Janusz Golus

Janusz Golus

Janusz Golus is a Busi­ness Devel­op­ment Man­ager at Philips Healthcare.

He received his M.Sc. and Ph.D. degrees in chem­istry from the Jagiel­lon­ian Uni­ver­sity in Kraków. He held two years post­doc­toral posi­tion at the Mar­quette Uni­ver­sity in Mil­wau­kee, United States, where he devel­oped a new method for syn­the­sis of selec­tively deutered Ru(bPy)³ com­plexes and their deriv­a­tives that enabled the con­ver­sion of solar energy into other forms of energy. His research attracted fund­ing from the US Depart­ment of Energy and US National Health Insti­tute, and its results were pub­lished in sev­eral pres­ti­gious aca­d­e­mic jour­nals, incl. the Jour­nal of Amer­i­can Chem­i­cal Society.

From aca­d­e­mics, Janusz tran­si­tioned into health­care indus­try. Between 1995 and 1997 he suc­cess­fully intro­duced Abbott phar­ma­ceu­ti­cals, incl. Klacid and Forane, to the Pol­ish mar­ket, by engag­ing and man­ag­ing a team of sales rep­re­sen­ta­tives, first at Gremi Farm and later directly at Abbott Lab­o­ra­to­ries. In 1997 he trans­ferred to GE Health­care where he was an Account Man­ager respon­si­ble for sales of diag­nos­tic equip­ment in south­east­ern Poland. In this capac­ity he con­tributed to the estab­lish­ment and growth of sev­eral diag­nos­tic imag­ing com­pa­nies, incl. Helimed, Euromedic, Voxel and Med-​Sport.

In 1999, Janusz and his wife Monika cofounded Scan­med, today the largest pri­vate health­care clinic in south­east­ern Poland.

In 2008 he trans­ferred to Philips, where he is cur­rently assist­ing Philips clients and their part­ners in the devel­op­ment of inno­v­a­tive health­care ser­vices and research projects by lever­ag­ing EU and national fund­ing for tech­nol­ogy trans­fer projects.

He resides in Kraków, but spends his week­ends in a small vil­lage in Beskid Wyspowy. He enjoys trav­el­ing, read­ing books and gar­den­ing. He has been hap­pily mar­ried for 37 years and has three sons.

He can be con­tacted at janusz.golus[at]philips.com


Leszek Grabarczyk

Leszek Grabar­czyk

Leszek Grabar­czyk, Deputy Direc­tor, National Cen­tre for Research and Devel­op­ment (NCBR)

Since 2011, Leszek Grabar­czyk has been Deputy Direc­tor of the National Cen­tre for Research and Devel­op­ment (NCBR) – a gov­ern­ment agency with an annual bud­get of PLN 5.5bn which sup­ports the R&D sec­tor in Poland. He is respon­si­ble for the devel­op­ment and imple­men­ta­tion of pro­grammes that pro­mote inno­va­tion and research com­mer­cial­i­sa­tion. In 2014, the NCBR has launched BRIdge – a fam­ily of pro­grammes that con­sti­tute Poland’s first ever sys­tem of financ­ing new tech­nolo­gies by the public-​private part­ner­ship while using pri­vate equity funds together with the world’s largest enti­ties of this type. Thanks to the activ­i­ties of the NCBR, Poland’s R&D expen­di­ture in 2012 achieved a record result of PLN14.4 bil­lion – almost 23% more than in the pre­vi­ous year.


Jeffery Grady

Jef­fery Grady

Jef­fery Grady has over 25 years build­ing busi­nesses across a vari­ety of sec­tors. He is cur­rently COO of Pro­teon Phar­ma­ceu­ti­cals S.A. of Poland, where he is assist­ing the CEO in speed­ing up devel­op­ment, rais­ing cap­i­tal and devel­op­ing the com­mer­cial­iza­tion approach of the company.

Mr. Grady has been involved in a large num­ber of star­tups and sig­nif­i­cant ‘turn­arounds.’ The start-​ups were in sev­eral sec­tors; the ‘turn­arounds’ ranged from a large multi­na­tional with sales in 12 coun­tries to a smaller tech­nol­ogy company.

Mr. Grady has also been in Pri­vate Equity (COO of Coper­ni­cus Capital-​an Affil­i­ate of Advent in Poland); High-​Tech Ven­ture Cap­i­tal (as a mem­ber of the Invest­ment Com­mit­tee of an Israeli High-​Tech VC Fund), and as an ‘active’ Angel investor in Poland and the USA.

Mr. Grady has a B.A. and M.A. from the Uni­ver­sity of Vir­ginia and an MBA from Yale Uni­ver­sity. His early career involved tech­nol­ogy eval­u­a­tion and research meth­ods — includ­ing co-​authoring an arti­cle on the Eval­u­a­tion of Anti-​Tank War­head technology.


Regina Hodits

Regina Hodits

Regina Hodits stud­ied chem­i­cal engi­neer­ing in Vienna and holds a PhD in bio­chem­istry. She was a researcher at the Uni­ver­sity of Vienna and the MRC Cen­tre for Pro­tein Engi­neer­ing before join­ing McK­in­sey. She focuses on early-​stage and growth deals in Life Sci­ences. Until Jan­u­ary 2010, she led the life sci­ences efforts of Atlas Ven­ture in Europe where she was the found­ing investor in Bicy­cle Ther­a­peu­tics, F-​star and Jenavalve. Regina served on sev­eral Boards, includ­ing the Board of U3 Pharma, which was acquired by Dai­ichi Sankyo Co. Ltd in 2008 and Novamed, which was acquired by Sci­Clone in 2010. From 2000 to 2004, while work­ing for Apax Part­ners, she was respon­si­ble for health­care invest­ments in Ger­many and was closely involved in invest­ments such as Gen­mab and Silence Ther­a­peu­tics. She is cur­rently a Gen­eral Part­ner at Welling­ton Part­ners and rep­re­sent the Welling­ton Part­ners funds on the Board of Mid­dle Peak Med­ical, Ayoxxa, Sapi­ens and Atopix, and is an exter­nal direc­tor at GlaxoSmithKline’s Res­pi­ra­tory TA Board.


Krzysztof Jakubczak

Krzysztof Jakubczak

Krzysztof Jakubczak is a grad­u­ate from the Insti­tute of Opto­elec­tron­ics of the Mil­i­tary Uni­ver­sity of Tech­nol­ogy, War­saw, Poland. He achieved his PhD in the tech­ni­cal sci­ences from the Czech Tech­ni­cal Uni­ver­sity in Prague. His tech­ni­cal back­ground is in mil­i­tary tech­nolo­gies, lasers, optics (clas­si­cal, X-​ray and EUV), infrared tech­nol­ogy, light mod­u­la­tion and detec­tion, sec­ondary sources for nano­lith­o­g­ra­phy, vac­uum sys­tems and spec­troscopy. Krzysztof is an expe­ri­enced R&D engi­neer. As Deputy Project Man­ager he worked on design of HiLASE laser research cen­ter and estab­lish­ment of coop­er­a­tion with the par­ties. He led the R&D team as a Research Pro­gram Leader work­ing on devel­op­ment of lasers for indus­trial appli­ca­tions. His com­mer­cial expe­ri­ence cov­ers pro­duc­tion engi­neer­ing and R&D projects in med­ical devices as well as new star­tups. In march 2014 he joined LSBC as the Oper­a­tions Direc­tor within Bridge Men­tor Project to com­mer­cial­ize Life Sci­ence inven­tions in Poland. He man­ages the team of com­mer­cial­iza­tion experts and assesses com­mer­cial poten­tial of med­ical devices and tech­ni­cal projects.


Roland Kozlowski

Roland Kozlowski

Roland Kozlowski received a first class hon­ours degree from the Uni­ver­sity of Bath and a PhD from the Uni­ver­sity of Cam­bridge. He is a bioen­tre­pre­neur who has worked in the indus­try for approach­ing two decades. Roland has held a num­ber of oper­a­tional roles includ­ing most recently Chief Exec­u­tive Offi­cer and a founder of Lec­tus Ther­a­peu­tics Lim­ited (investor exit via asset sale to UCB in Q4, 2011), Chief Exec­u­tive Offi­cer and co-​founder of Sense Pro­teomic Lim­ited (trade sale to Procog­nia Lim­ited in Q1, 2003). In the mid 1990s Roland worked with Oxford Mol­e­c­u­lar PLC on their cor­ner­stone deal he nego­ti­ated with Yamanouchi Phar­ma­ceu­ti­cal Co., Ltd. Dur­ing his career Roland has gained con­sid­er­able trans­ac­tional expe­ri­ence rang­ing from com­pany sale, pur­chase, financ­ing and in– and out-​licensing and com­mer­cial­i­sa­tion of tech­nol­ogy. In the past Roland ran a Research Groups at the Uni­ver­sity of Oxford and Uni­ver­sity of Bris­tol where sub­se­quently he was a Vis­it­ing Indus­trial Pro­fes­sor. He has pub­lished and patented in the field of ion chan­nel phys­i­ol­ogy and phar­ma­col­ogy. Roland has served on the boards of a num­ber of com­pa­nies includ­ing the Bio-​Industry Asso­ci­a­tion in the UK. He remains a direc­tor of Lec­tus Ther­a­peu­tics Lim­ited and is presently non-​executive direc­tor of Lon­don Genet­ics Lim­ited which oper­ates in the per­son­alised med­i­cine space, Chief Strat­egy Offi­cer of BTM Mazowsze Sp. z o. o. a com­pany set up to com­mer­cial­ize inno­va­tion emerg­ing from the lead­ing life sci­ence research insti­tu­tions in Warsaw.


Klaus Mar­tin

Klaus Mar­tin is the Senior Direc­tor of Pol­pharma Bio­log­ics lead­ing its global busi­ness and prod­uct and devel­op­ment activ­i­ties. With his broad expe­ri­ence in strat­egy and devel­op­ment of Biosim­i­lars and Bio­bet­ters. Klaus joined Pol­pharma to set up its Bio­log­ics busi­ness in Octo­ber 2010. Prior to Pol­pharma, for eight years he held global man­age­ment posi­tions at San­doz Bio­phar­ma­ceu­ti­cals, first as Devel­op­ment Project Leader, e.g. for San­doz’ fil­gras­tim and, a.i. for their rit­ux­imab biosim­i­lars, then as Head of Global Pre-​clinical and Clin­i­cal devel­op­ment and finally as Head of BD&L and Port­fo­lio Man­age­ment as a mem­ber of the Bio­phar­ma­ceu­ti­cals Exec­u­tive Com­mit­tee. His teams helped bring to the mar­ket San­doz’ first three biosim­i­lars in the EU, US and Japan.Klaus is a bio­chemist by train­ing and holds a PhD in Pathol­ogy from the Uni­ver­sity of Cam­bridge. Before join­ing the phar­ma­ceu­ti­cal indus­try, he spent three years as a strat­egy con­sul­tant with OC&C advis­ing inter­na­tional clients in a vari­ety of industries.


Edyta Niemczyk

Edyta Niem­czyk

Edyta Niem­czyk grad­u­ated from Inter­col­le­giate Fac­ulty of Biotech­nol­ogy, Uni­ver­sity of Gdańsk and Med­ical Uni­ver­sity of Gdańsk. She received a PhD in mol­e­c­u­lar biol­ogy from Med­ical Uni­ver­sity of Gdańsk, super­vised by excel­lent sci­en­tist from Nagoya Med­ical Uni­ver­sity in Japan – Prof. Takashi Wak­abayashi, who was a famous spe­cial­ist in pathol­ogy of mitochondria.

In order to fol­low the career path­way she envis­aged, she applied for the Post­doc­toral Research Asso­ciate posi­tion at the Uni­ver­sity of Liv­er­pool in UK with the pos­i­tive out­come. Dur­ing the two-​year con­tract she was acquainted with Sin­gle Nucleotide Poly­mor­phism (SNP) geno­typ­ing using Illu­mina arrays for the pur­pose of Famil­iar Pan­cre­atic Can­cer inves­ti­ga­tion. The next step for her career was to par­tic­i­pate in the project that would con­sider SNPs analy­sis using the most advanced tech­nol­ogy and analy­sis tools. That oppor­tu­nity was given to her at the Uni­ver­sity of Birm­ing­ham, when she was appointed for the Post­doc­toral Fel­low posi­tion where she was pas­sion­ately ana­lyz­ing asso­ci­a­tion of the genetic loci with acute ante­rior uveitis onset.

Edyta is expe­ri­enced geneti­cist per­fectly join­ing the pas­sion for the sci­ence and its com­mer­cial­iza­tion. Her key respon­si­bil­i­ties at LSBC as the Junior Com­mer­cial­iza­tion Expert are to assess prop­erly the sci­en­tific and com­mer­cial strengths of ana­lyzed projects.


Lukasz Nieradko

Lukasz Nier­adko

Dr. eng. Lukasz Nieradko

Direc­tor of Busi­ness Devel­op­ment Department

Lukasz Nier­adko is grad­u­ated in elec­tron­ics of Wro­claw Uni­ver­sity of Tech­nol­ogy. He received MSc and PhD degree in 1996 and 2002 respec­tively. His doc­toral the­sis – defended with hon­ors – con­sid­ered devel­op­ment of CMOS com­pat­i­ble tech­nol­ogy of the first in the world inte­grated on-​chip micro­colum for gas chro­matog­ra­phy with porous sil­i­con active layer act­ing as sta­tion­ary phase. This tech­nol­ogy opened pos­si­bil­i­ties to built minia­ture, portable sys­tems for µTAS type gas ana­lyzer for coal mine indus­try. Dur­ing his stud­ies, he par­tic­i­pated as in research pro­grams, focused on devel­op­ment of tech­nol­ogy of sil­i­con pres­sure sen­sors, accel­er­a­tors and MEMS devices. His research activ­i­ties were awarded on sev­eral con­fer­ences, he won team prize of Asso­ci­a­tion of Pol­ish Elec­tri­cal Engi­neers SEP, prize of Pres­i­dent of War­saw Uni­ver­sity of Tech­nol­ogy. Dr Nier­adko is a post-​fellow of Foun­da­tion of Pol­ish Sci­ence. Since 2001 to 2003 he joined Uni­ver­sity of Franche-​Comte, as post-​doc fel­low of Marie Curie Indi­vid­ual Fel­low­ship, where he has con­ducted R&D activ­i­ties in the field of inte­grated microop­tics – MOEMS, work­ing of novel types of move­ment, vibra­tion and pres­sure sen­sors in the frame of 5th FPOCMMM (Opti­cal Char­ac­ter­i­za­tion Meth­ods of MEMS Man­u­fac­tur­ing). In 2004 he joined CNRS (Cen­tre National d’Recherche Sci­en­tific) as Research Engi­neer, work­ing in research projects of DGA (Direc­tion Générale de l’Armement), CNES (Cen­tre National d’Études Spa­tiales) and ANR (Agence Nationale de la Recherche) on inte­grated on-​chip atomic clock. His research inter­est on inte­grated microop­tics were real­ized in FP6 – Net­work of Excel­lence in Micro Optics (NEMO) – project devel­op­ing var­i­ous MOEMS devices, tech­nolo­gies of glass and plas­tic opti­cal micro­com­po­nents of minia­ture con­fo­cal micro­scope. Dr Nier­adko is author of patent and sci­en­tific pub­li­ca­tions. He is a mem­ber of PTTS (Pol­ish Soci­ety of Sen­sors Tech­nol­ogy) and MCFA (Marie Curie Fel­low Association).

Dr Nier­adko joined WCB EIT+ on June 2008 as Coor­di­na­tor of Research and Infra­struc­ture Devel­op­ment in field of nan­otech­nol­ogy. Cur­rently he holds a posi­tion of Direc­tor of Busi­ness Devel­op­ment Depart­ment. He is respon­si­ble i.a. for com­mer­cial­iza­tion, estab­lish­ing col­lab­o­ra­tions and alliances with com­pa­nies, devel­op­ment of new com­mer­cial projects, as well as an imple­men­ta­tion of new tech­nolo­gies to Partners.


Marta Oseka

Marta Oseka

Marta Osęka has dual edu­ca­tional back­ground in the field of Eco­nom­ics and Pro­duc­tion Engi­neer­ing (War­saw Uni­ver­sity of Tech­nol­ogy). Since 2005, she has dealt with col­lab­o­ra­tion between sci­ence and busi­ness. She focuses on obtain­ing financ­ing for R&D projects, cre­at­ing busi­ness strate­gies, opti­miz­ing an invest­ment costs and project man­age­ment. She has been col­lab­o­rated with the Deloitte (as a Man­ager at the R&D and Gov­ern­ment Incen­tives Depart­ment), and with the VC funds – INVESTIN (as a Project and Tech­nol­ogy Man­ager), also with many Pol­ish and for­eign R&D cen­tres (as a research spe­cial­ist, a project coor­di­na­tor or an advisor).

Marta’s key respon­si­bil­ity at the LSBC as a Busi­ness Devel­op­ment Asso­ciate is to pro­vide essen­tial sup­port for research projects in busi­ness devel­op­ment stage.


Maciej Paszewski

Maciej Paszewski

Maciej Paszewski stud­ied chem­istry in War­saw and holds a PhD in organic chem­istry. He was a researcher at the North­west­ern Uni­ver­sity and the Insti­tut of Phys­i­cal Chem­istry Pol­ish Acad­emy of Sci­ences before join­ing Orenore, a pol­ish VC found. In Orenore he was respon­si­ble for acqui­si­tion and eval­u­a­tion of projects in the area of life sci­ence. Maciej led to cre­ation of Nanox­ide – a start-​up com­pany devel­op­ing new flu­o­res­cent probes for biol­ogy and med­i­cine based on newly dis­cov­ered zinc clus­ters. As a direc­tor in Nanox­ide he was respon­si­ble for R&D strat­egy, IP pro­tec­tion, mar­ket and com­pe­ti­tion analy­sis and rais­ing exter­nal funds. Maciej col­lab­o­rated with AstraZeneca as a clin­i­cal trial monitor.

In 2013 he has joined LSBC. He is cur­rently a Senior Com­mer­cial­iza­tion Asso­ciate at LSBC where he is respon­si­ble for project eval­u­a­tion, men­tor­ing and writ­ing busi­ness pro­pos­als. He par­tic­i­pates in Bridge Men­tor jointly imple­mented by LSBC and The National Cen­ter for Research and Development.


Steven Powell

Steven Pow­ell

Steven Pow­ell, Oper­a­tional Part­ner, Gilde Healthcare

Steven has over 25 years oper­a­tional and invest­ment expe­ri­ence in phar­ma­ceu­ti­cal and life sci­ence R&D at com­pa­nies includ­ing Beecham Phar­ma­ceu­ti­cals (GSK), What­man, Chi­ro­science, Cel­sis, Active Biotech, KS Bio­medix and Plethora Solu­tions. Dur­ing his oper­a­tional career he has held four CEO roles, two in pub­lic com­pa­nies. He joined Gilde Health­care, a pan-​European life sci­ences invest­ment fund, in 2003. Steven has co-​founded 4 com­pa­nies of which 2 have been sold and con­cluded over 40 licens­ing agree­ments and 7 M&A trans­ac­tions. Steven grad­u­ated in micro­bi­ol­ogy from the Uni­ver­sity of Wales and was awarded a PhD from the Uni­ver­sity of Aberdeen.


Pawel Przewiezlikowski

Pawel Przewie­z­likowski

Pawel Przewie­z­likowski, co-​founded Selvita in 2007 and is the Chief Exec­u­tive Offi­cer of the com­pany, respon­si­ble for strate­gic man­age­ment, busi­ness and cor­po­rate devel­op­ment. He is also the Chief Exec­u­tive of Bio­Cen­trum, Selvita’s daugh­ter com­pany. Mr. Przewie­z­likowski is a mem­ber of the Eco­nomic Coun­cil of the Mal­opol­ska (Krakow) region as well as of the Mal­opol­ska Inno­va­tion Coun­cil. From 1994 to 2007 he worked at ComArch, a Pol­ish infor­ma­tion tech­nol­ogy com­pany. As a man­age­ment board mem­ber since 1996, he was respon­si­ble for the divi­sions offer­ing solu­tions for the phar­ma­ceu­ti­cal, bank­ing, man­u­fac­tur­ing and ser­vices indus­tries and took part in the organic trans­for­ma­tion of a uni­ver­sity spin-​off to the largest organ­i­cally grown IT com­pany in Cen­tral and East­ern Europe, employ­ing over 2 700 peo­ple in 20 coun­tries. Dur­ing his time at ComArch in 19992000 he was also the co-​founder and the first CEO of Inte​ria​.pl, the third largest por­tal in Poland. Mr. Przewie­z­likowski holds an MBA from the joint pro­gram of the Uni­ver­sity of Teesside (United King­dom) and Krakow School of Eco­nom­ics (Poland) as well as mas­ter degree in com­puter sci­ence from AGH Tech­ni­cal Uni­ver­sity in Krakow.


Mike Romanos

Mike Romanos

Mike Romanos is CEO and founder of Crescendo Bio­log­ics Ltd, a VC-​backed Cam­bridge based com­pany that has devel­oped an inno­v­a­tive trans­genic plat­form for gen­er­at­ing human sin­gle domain anti­body ther­a­peu­tics. He has 25 years’ biotech and phar­ma­ceu­ti­cal indus­try expe­ri­ence in bio­logic and NCE drug dis­cov­ery across sev­eral ther­a­peu­tic areas, start­ing with Well­come Biotech, an early pio­neer in UK biotech­nol­ogy, in the 1980s.

Pre­vi­ous to his cur­rent role, Mike held lead­er­ship posi­tions for over 10 years in Glax­o­SmithK­line R&D, build­ing and man­ag­ing global Dis­cov­ery organ­i­sa­tions that made a major impact in tar­gets, tech­nol­ogy and pipeline projects. In par­tic­u­lar, Mike played a key role in estab­lish­ing GSK’s anti­body lead dis­cov­ery capa­bil­ity which gen­er­ated a pipeline of in-​house mon­o­clonal anti­bod­ies, sev­eral of which are in clin­i­cal development.

Mike holds a degree in Nat­ural Sci­ences from Cam­bridge Uni­ver­sity, a PhD in Mol­e­c­u­lar Virol­ogy from Impe­r­ial Col­lege, and under­took post­doc­toral research in Virol­ogy at the MRC’s National Insti­tute for Med­ical Research and in Yeast Biotech­nol­ogy at Leices­ter Bio­cen­tre. He is cur­rently a panel mem­ber of the MRC’s Devel­op­men­tal Path­way Fund­ing Scheme, which funds trans­la­tional stud­ies through pre­clin­i­cal and early clin­i­cal devel­op­ment, and a Fel­low of the Soci­ety of Biology.


Benjamin Thiering

Ben­jamin Thiering

Ben­jamin Thier­ing joined the Health Care Indus­tries Unit at Berlin Part­ner for Busi­ness and Tech­nol­ogy, the Berlin Eco­nomic Devel­op­ment Agency, in 2013. He holds a degree in eco­nomic geog­ra­phy from Humboldt-​Universität zu Berlin and started his life sci­ence career with his the­sis in the Busi­ness Devel­op­ment of Fraun­hofer Insti­tute for Cell Ther­apy and Immunol­ogy (IZI) in Leipzig in 2010. After work­ing in the eco­nomic devel­op­ment for the Ger­man state of Hesse, Ben­jamin is now respon­si­ble for sup­port­ing Biotech & Pharma com­pa­nies in their relo­ca­tion and start-​up ven­tures in the Ger­man Cap­i­tal region.


Alexander Yule

Alexan­der Yule

Dr Alexan­der Yule (Prin­ci­pal, Alexan­der Yule Con­sult­ing). Alexan­der Yule is a com­mer­cial and cor­po­rate sup­port pro­fes­sional with over 23 years’ expe­ri­ence at senior exec­u­tive level as either an employee, interim man­ager or long term advi­sor within pri­vate and pub­lic life sci­ence and phar­ma­ceu­ti­cal com­pa­nies in the UK, Scan­di­navia and North Amer­ica. He has been involved in the com­mer­cial­i­sa­tion of prod­ucts and tech­nolo­gies across oncol­ogy, CNS, urol­ogy, infec­tious dis­ease, clin­i­cal diag­nos­tics, med­ical devices and OTC/​consumer health­care. Alex par­tic­u­larly enjoys work­ing with pre-​money/​start-​up and small-​cap com­pa­nies but also works with mid-​cap and global health­care com­pa­nies. He has sup­ported numer­ous suc­cess­ful LSE/​AIM list­ings, pri­vate place­ments and M&A transactions.


Dominik Zietkowski

Dominik Zietkowski

Dominik Zietkowski is a Research and Devel­op­ment Direc­tor at BLIRT S.A., a pol­ish inno­v­a­tive biotech­nol­ogy com­pany located in Gdansk. He received his M.Sc. in biotech­nol­ogy form the Uni­ver­sity of Gdansk and a Ph.D. degree in bio­physics from the Uni­ver­sity of Lon­don. For 4,5 years he held doc­toral and post­doc­toral posi­tions at the Insti­tute of Can­cer Research and the Royal Mars­den Hos­pi­tal in Lon­don where he was work­ing on bio­marker dis­cov­ery and an inno­v­a­tive anti­cancer com­pounds devel­op­ment. In 2011 he joined R&D team at Blirt S.A., ini­tially as a project man­ager, then as a Head of R&D, where he was respon­si­ble for the devel­op­ment of company’s in house drug dis­cov­ery, R&D projects in oncol­ogy and anti­fun­gals. He also serves as a deputy CEO in BS-​154 sp. z o.o. and Trans­medium sp. z o.o., Blirt’s two spin-​off com­pa­nies devel­op­ing an inno­v­a­tive oncol­ogy drug can­di­date and a trans­plan­tol­ogy ded­i­cated med­ical device, respectively.


Romeer Fernandes

Romeer Fer­nan­des

Romeer Fer­nan­des is a com­mer­cial leader with a 15-​year track record of suc­cess­fully build­ing med­ical devices and phar­ma­ceu­ti­cal busi­nesses in Europe and Asia with blue-​chip multi­na­tion­als (e.g. Medtronic, Glax­o­SmithK­line) and start-​ups. He cur­rently works as an inde­pen­dent con­sul­tant in interim man­age­ment roles with medtech start-​ups in Switzer­land. He recently devel­oped and rolled-​out the Go-​to-​market strat­egy for Symetis, a Swiss start-​up that launched an inno­v­a­tive trans-​cathteter valve, achiev­ing the first mil­lion dol­lars in rev­enue within 3-​months of CE approval. Romeer has a degree in Mol­e­c­u­lar Biol­ogy (Univ of Cam­bridge, UK) and an MBA (IMD, Switzerland)


Mariusz Olejniczak

Mar­iusz Olejniczak

Mar­iusz Ole­jniczak is Gen­eral Man­ager and share­holder of Assign Clin­i­cal Research Sp. z o.o. Assign Clin­i­cal Research Sp. z o.o. is a mem­ber of Assign Group and The Biosim­i­lars Group. Both orga­ni­za­tions pro­vide ser­vices espe­cially in clin­i­cal oper­a­tions and man­u­fac­tur­ing of inves­ti­gated med­i­c­i­nal prod­ucts. In addi­tion, Mar­iusz works in the field of e/​m-​Health as CEO of e-​clincial start-​up Monitor-​CR sp. z o.o. and pro­vides con­sult­ing ser­vices for com­pa­nies and start-​ups devel­op­ing phar­ma­ceu­ti­cals and med­ical devices. He was orig¬i¬nally trained in biotech­nol­ogy and sub­se­quently was work¬ing in sci­ence and mar¬ket¬ing in the med­ical devices and trans­plan­ta­tion fields. Mar­iusz is mem­ber of the board of Asso­ci­a­tion for Good Clin­i­cal Prac­tice in Poland.


Bogusław Sieczkowski

Bogusław Sieczkowski

Mr. Bogus­law Sieczkowski is a co-​founder of Selvita and cur­rently holds the posi­tion of the Exec­u­tive Vice Pres­i­dent, as well as the Chief Oper­at­ing Offi­cer. Mr. Sieczkowski has a solid edu­ca­tion and over 15 years of expe­ri­ence in man­age­ment. His career was ini­ti­ated in the mid­dle nineties super­vis­ing com­put­er­i­za­tion of com­pa­nies within Bahlsen group. Since 2000 as a board mem­ber of Comarch Inter­net Ven­tures S.A. he devel­oped the first ASP Ser­vices plat­form in Poland. Till 2007, as a Vice Pres­i­dent of Comarch S.A. he was in charge of the largest sub­sec­tor (250 peo­ple) deliv­er­ing prod­uct for lead­ing sci­en­tific and finance insti­tu­tions. Mr. Sieczkowski holds an MBA from joint pro­gramme of the Uni­ver­sity of Teesside (United King­dom) and Krakow School of Eco­nom­ics (Poland), mas­ter degree in com­puter sci­ence from Jagiel­lon­ian Uni­ver­sity in Krakow as well as Project Man­age­ment Pro­fes­sional cer­tifi­cate issued by Project Man­age­ment Insti­tute (United States). His hob­bies are ski­ing and tourism.


Mark Treherne

Mark Tre­herne

Mark has been actively involved in the bio­phar­ma­ceu­ti­cal indus­try for 25 years and was a co-​founder and Chief Exec­u­tive of Cam­bridge Drug Dis­cov­ery Lim­ited, lead­ing the Company’s acqui­si­tion by Bio­Fo­cus plc, where he then became a Com­mer­cial Direc­tor, dri­ving sig­nif­i­cant growth of its prof­itable ser­vices busi­ness. Mark has now served on the Boards of 13 pri­vate and pub­lic bio­phar­ma­ceu­ti­cal com­pa­nies and is cur­rently on the Boards of Cycloflu­idic, Domain Ther­a­peu­tics, Pop­u­la­tion Genet­ics Tech­nolo­gies and Senexis. Dr Tre­herne has now helped raise more than £140 mil­lion for var­i­ous bio­phar­ma­ceu­ti­cal busi­nesses over the last decade. Mark was also for­merly Chair­man of ERBI Lim­ited, which is a not-​for-​profit organ­i­sa­tion that rep­re­sents the biotech­nol­ogy com­pa­nies based around Cam­bridge in the East of Eng­land. Mark ini­tially trained as a neu­ro­sci­en­tist and elec­tro­phys­i­ol­o­gist at Cam­bridge Uni­ver­sity. Mark joined the Life Sci­ence Invest­ment Organ­i­sa­tion as Chief Exec­u­tive, fol­low­ing its for­ma­tion by UK Trade and Investment.


Marcin Szumowski

Marcin Szu­mowski

Marcin Szu­mowski is ser­ial entre­pre­neur. He received his MS and PhD degrees from the Uni­ver­sity of Illi­nois and earned an MBA degree in entre­pre­neur­ship and inter­na­tional finance. Fol­low­ing a suc­cess­ful research career in the United States, Marcin has been involved in tech­nol­ogy trans­fer and start-​up com­pa­nies since 2000 and has co-​founded and man­aged five start-​ups, includ­ing a med­ical diag­nos­tics com­pany Med­ical­go­rith­mics, where he was Pres­i­dent and CEO dur­ing 20052010. Med­ical­go­rith­mics SA is now traded on the War­saw Stock Exchange with a mar­ket cap of approx. $230M and its prod­ucts are sold glob­ally. Since 2012 he is Pres­i­dent & CEO of OncoArendi, a Pol­ish inno­v­a­tive bio­phar­ma­ceu­ti­cal com­pany ded­i­cated to devel­op­ing and com­mer­cial­iz­ing novel ther­a­peu­tics for neo­plas­tic and inflam­ma­tory dis­eases. Over the last 15 years Marcin has man­aged approx. 40 R&D and invest­ment projects with a total value of over 200M euro.


Adam Kruszewski

Adam Kruszewski

Adam Kruszewski is an expert and man­ager, with over 25 years of man­age­ment and busi­ness devel­op­ment expe­ri­ence in the area of: Drug/​Devices Devel­op­ment Mar­ket, Health Care Mar­kets, Finan­cial Mar­kets. Invented and devel­oped a num­ber of busi­ness projects and sup­port activ­i­ties For 9 years Pres­i­dent & Share­holder of KCR – the fastest grow­ing CRO in CEE Region. Cur­rently CEO/​Chairman & main share­holder of pHase2microtechnology, a high-​tech com­pany based in Pitts­burgh, PA.

Media

  • media1
  • media2

Atten­dees

Organ­i­sa­tions that have attended in the past:

Abcam

Aca­dia

Activ­iomics Ltd

Adamed

Amgen

Amrop

Appo­site Capital

Aquar­ius Fund

Assign Clin­i­cal Group

Babra­ham Bio­science Technologies

Ban­ner Group

Biotech Con­sult­ing

Biovec­tis

BLIRT

Boehringer Ingel­heim Pharma GmbH & Co KG

BTM Mazowsze

Bur­rill & Company

CIT­TRU

Crescendo Bio­log­ics Ltd

Deloitte

demosEU­ROPA

Dutch Biore­fin­ery Cluster

eFab­rica

EJ Palmer Consulting

Enter­prise Investors

Epither­a­peuitcs

EQT Part­ners

Euro­pean Commission

Euro­pean Invest­ment Fund

For­bion

FutureSyn­the­sis

Gideon Richter

Hep­endo Sp. z o. o.

Hep­tares Therapeutics

Hori­zon Discovery

Hun­gar­ian Biotech Asso­ci­a­tion (HU)

Impe­r­ial Innovations

Index Ven­tures

Nencki Insti­tute of Exper­i­men­tal Biology

Novozymes

Insty­tut Chemii Bioor­gan­icznej PAN

Insty­tut Farmaceutyczny

IOCB TTO

Jadara Pharma Ltd

Jagiel­lon­ian Uni­ver­sity, JCET

Jagiel­lońskie Cen­trum Innowacji

Lon­don Genet­ics International

MCI

Med­ical Research Coun­cil Tech­nol­ogy Group (MRCT)

Med­ical­go­rith­mics S.A.

Med­Im­mune Ltd

Medi­vir AB

Medtronic

Merck

National Cap­i­tal Fund

NBGI Ven­tures

Nickel Devel­op­ment

Orenore Sp. z o.o.

Osborne Clarke

Pol­ish Stock Exchange

Pol­pharma

ProPharma Part­ners Ltd

Pro­teon

Prox­im­a­gen

Pure Bio­log­ics s.c.

Royal Asso­ci­a­tion of Dutch Paper and Board Industries

RTC Inno­va­tion Ltd

QIA­GEN

Quin­tiles

Sage Health­care

Selvita S.A.

Sem­ple Fraser LLP

Seroba-​Kernel (UK/​IR)

Sitra

Sofinnova

South Mora­vian Inno­va­tion Centre

Takeda Research Investment

Tay­lor Wessing

The John Paul II Hospital

The National Cen­tre for Research & Development

The Pol­ish Agency for Enter­prise Development

TVM

UK Trade and Investment

Med­ical Uni­ver­sity Lodz

USP Life Sciences

Wro­claw Research Cen­tre EIT+

Dis­claimer

CAN­CEL­LA­TION POL­ICY & DISCLAIMER

Life Sci­ence Biznes Con­sult­ing (LSBC) Sp. z o. o. allows a change of reg­is­trant at no extra cost if the orig­i­nal reg­is­trant is unable to attend.

In the event of can­cel­la­tion of the Con­fer­ence by the orga­niz­ers all fees paid by del­e­gates will be returned in full although Life Sci­ence Biznes Con­sult­ing (LSBC) Sp. z o. o. is not respon­si­ble for any other finan­cial losses such as travel and hotel costs.

In the event that a del­e­gate or accom­pa­ny­ing per­son can­cels atten­dance at the con­fer­ence Life Sci­ence Biznes Con­sult­ing (LSBC) Sp. z o. o. will return 60% of the reg­is­tra­tion fee if atten­dance is can­celled before Fri­day 19 Sep­tem­ber 2014. There­after there will be no return of fees.

Life Sci­ence Biznes Con­sult­ing (LSBC) Sp. z o. o. is not liable in any way for any injuries, sick­ness or acci­dent or any costs incurred as a con­se­quence of such an event or any other losses to which a del­e­gate or accom­pa­ny­ing per­son may be sub­jected to whist trav­el­ling to or from Poland or whilst attend­ing the con­fer­ence in Krakow or any of the social events organized.

The speak­ers listed have all con­firmed their atten­dance and have agreed to post their pho­tographs on this web­site. How­ever Life Sci­ence Biznes Con­sult­ing (LSBC) Sp. z o. o. informs del­e­gates and speak­ers that that the final agenda could change for rea­sons beyond its con­trol. Life Sci­ence Biznes Con­sult­ing (LSBC) Sp. z o. o. reserves the right to make changes to the agenda and is not respon­si­ble for any finan­cial losses or costs incurred by par­tic­i­pants or del­e­gates in asso­ci­a­tion with their par­tic­i­pa­tion at this conference.

Spon­sors

main patron

NCBR
innovative-economy
eu

spon­sors

British Embassy Warsaw PZU Inwestycje
assign selvita
CelonPharma Polpharma

part­ners

parp UK Trade
Bussiness Is Great Britain Jagiellonian Center of Innovation
UJ>

media part­ner

biotechnologia Berlin Partner
Pharmaceutical European Biotechnology
iitolse Bio Partner

Hotels

rec­om­mended hotels

Qubus Hotel Hotel Wawel Andel's Hotel
Hotel Stary Hotel Amadeus Hotel Maltański
Hotel Polski Hotel Unicus Hotel Wit Stwosz

LSBC has obtained pref­er­en­tial rates at these hotels which rep­re­sent a 10 to 25% dis­count on their stan­dard tar­iff. Please book as nor­mal quot­ing “LSBC con­fer­ence”. For more infor­ma­tion regard­ing detailed prices please con­tact: conference[at]lsbc.pl

Pre­sen­ta­tions

Pre­sen­ta­tions

Pre­sen­ta­tions were made acces­si­ble to all the LSBC con­fer­ence Atten­dees. If you expe­ri­ence any dif­fi­cul­ties with the access to the files, please con­tact the con­fer­ence organizer

MichalBanka

Catherine Beech

Glenn Crocker BioCity

Romeer Fernandes

Tomasz Goralczyk Polpharma

Leszek Grabarczyk NCRD

Jeffery Grady Proteon Pharmaceuticals

Krzysztof Jakubczak LSBC

Edyta Niemczyk LSBC

Mariusz Olejniczak Assign

Marta Oseka LSBC

Maciej Paszewski LSBC

Alexander Yule Consulting

Dominik Zietkowski BLIRT